



### **Thinking about Molecular Interactions in Drug Discovery**

Martin Stahl, Roche Basel, March 2013






## A Ligand in its Binding Site Shape Complementarity






### **Hydrogen Bonds Specific and Directed**




### Hydrophobic Interactions "Surface Contacts"








## More Interactions! A Continuum or Discrete Types?





#### "Interactions" are only Part of a Complex Reality







### **Learning about Interactions** *From Theoretical to Experimental*



$$\Delta G = \sum_{i=0}^{n} \Delta G_i$$






Method	Benefit	Caveat
Quantum chemistry	Exact energies & orientations	Gas phase only  Complex interpretation
Empirical force fields, scoring functions	Fast estimates	Contributions to energy sum easily over-interpreted
Statistical X-ray analysis	Net energetic estimates & good geometries	Choice of reference states Sampling bias No total energy
Experimental model Systems	Good upper and lower bounds for an interaction	Tedious, many expt. parameters, Context dependent

#### **Orthogonal Multipolar Interactions?**








Paulini, R.; Müller, K.; Diederich, F. Angew. Chem. Int. Ed. 2005, 44, 1788-1805.


#### Roche

### Fluorine and Carbonyl Groups in the CSD *C vs. O Interactions*






### P38 MAP Kinase Inhibitors Role of F Substituents in Back Pocket







# Chlorine vs. Fluorine *Halogen Bond more Frequent than Orthogonal Multipolar Interaction*



#### **Strong Halogen Bonding Effect in Cathepsin L**








R	IC <sub>50</sub> [nM]	
Н	290	) 10 fold
Cl	22	3-fold
F	340	
Br	12	
l	6.5	
Me	130	


#### **Binding Modes Adapt to Halogen Bonding**






#### **Flexible Pyrrolidine Ring Allows for Adjustment**







### **Changing the Halogen Bonding Angle Interaction with Cl-substituted 5-membered Rings**







$$CI$$
  $O = N-H$ 



#### **Conclusions: Halogen Bonding**




- Rigorous geometric requirements:
  - d (halogen--oxygen) ≤ sum of van der Waals radii
  - angle  $C-X-O \approx 140^{\circ}-180^{\circ}$  (optimal): steep angle dependency
  - angle X···O=C can vary between 90° and 180°
- I > Br > Cl
- No halogen bonding for aryl fluorides
- Establishing a halogen bond might enhance protein-ligand interactions by as much as a factor of 74 (X = H vs. X = I) which translates into a gain in free enthalpy of  $-\Delta\Delta G = 2.6$  kcal/mol


#### **SAR** in **S1** Pocket of Factor Xa



$$K_i = 146 \text{ nM}$$

Br 
$$\stackrel{N^+}{\longrightarrow}$$
  $\stackrel{N^+}{\longrightarrow}$   $\stackrel{N^-}{\longrightarrow}$   $\stackrel$ 







#### **Polarity of Amide Groups**



N-methylacetamide as model system




dipole moment: 3.8 Debye



electrostatic potential

#### Roche

#### Rotational Scan of Pyridine...N-methylacetamide



preference for close to anti-parallel alignment

#### **Dipole-dipole Interaction**



parallel dipoles, on top of each other:

$$U_{dipole-dipole} = \frac{f * \mu_1 * \mu_2}{r^3} * \cos \alpha$$

$$-0.5$$

$$-1.5$$

$$-2.0$$

$$-2.5$$

$$-3.0$$

$$0$$

$$0$$

$$180$$


$$240$$

$$300$$

$$360$$


### PDB Database Analysis Confirms Antiparallel Preference






#### Roche

### **Correlation between Interaction Energy and Dipole Moment**



#### **Trends in Interaction Energies**






Stacking interaction is improved with increasing dipole moment of the heterocycle

#### **Trends in Interaction Energies**






Stacking interaction is improved with decreasing  $\pi$ -electron density

#### Conclusions: Amide- $\pi$ Stacking



- Stacking energies of heteroarenes on amide  $\pi$  systems can be improved by:
  - proper orientation of the dipole moment vectors in an anti-parallel fashion
  - increasing the dipole moment of the heterocycle
  - decreasing its  $\pi$ -electron density.
- Ideal distances between both planes: 3.4-3.8Å
- Guidelines can be extended to other  $\pi$  systems, e.g. H-bonding arrays





#### **SAR** in **S1** Pocket of Factor Xa



$$\sum_{N}^{O} K_{i} = 146 \text{ nM}$$


$$\mathcal{K}_{i} = 1620 \text{ nM}$$





#### There is Never Only One Explanation Exit Vector Differences in Oxazoles







### It's Never Only About Interactions Dipole Moments and Physicochemical Parameters



log D 5.9 solubility, 7 μM

log D 4.0 solubility, 26 μM






V<sub>min</sub> values

### Non-Additivity Aminopyrimidine DPPIV Inhibitors







expected for combination: 500-fold






#### ... or Interaction Networks







#### Protein-Ligand Complex Modeled as a Small World Network




Addition of an extra node and just a few extra edges can reduce shortest path lengths between many pairs of nodes

Use network approach to capture cooperativity in protein-ligand complexes?


#### Roche

#### "Static" Cooperativity, e.g. Hydrogen Bond Networks



#### "Dynamic" Cooperativity






L. Muley et al. J. Med. Chem. 2010, 53, 2126-2135.


B. Baum et al. J. Mol. Biol. 2010, 397, 1042-1054.

### **Distinct Network Elements Involving Ligand and Protein Atoms**






ligand-protein-ligand "cycles"




ligand-protein-ligand "loops"



ligand-protein-protein (subsets of larger loops)

#### **Aurora A Kinase Inhibitors**






3d15


#### **Aurora A Kinase Inhibitors**






#### **Aurora A Kinase Inhibitors**





#### networked H-bonds with high score incl. network contribution




#### **How Valid is the Network Concept?**



- Forces to consider the complexity of molecular interactions
- Visualization is Key
- A template against which to judge reality
- Scoring function derived to get a feeling for relative magnitude of parameters
- Need far more examples (positive and negative) for robust selection of terms
- Alternatively, use as an expert system (highlight what's been observed before)
- A good network may just mean there is a good fit true even for fragments
- Current model still treats cooperativity as a very local phenomenon


#### **Beta-Lactamase Inhibitors**






#### Roche

### **Syn-Pentane Interactions Strongly Avoided**







VINTAN01 - Discodermolide



#### **Enalapril SAR**

#### Conformational Locking Avoiding Syn-Pentane Interactions

 $4.9 \, \mu M^{-1}$ 

 $260 \mu M^{-1}$ 

 $4.8 \,\mu M^{-3}$ 

$$HO \longrightarrow H \longrightarrow O \longrightarrow O$$


 $2.4~\mu M^{\ 2}$ 

0.09 μΜ

- 1. D. W. Cushman, et al., *Biochemistry* **1977**, 16, 5484-5491.
- 2. A. A. Patchett, ACS: Washington DC, 1993; Vol. 3, pp 125-163.
- 3.. P. Shi, P.; Wang, H. *Shandong Yixueyuan Xuebao (Acta Academiae Medicinae Shandong)* **1984,** 22, 44-48.




### **Enalapril / ACE Cocrystal Structure No Direct Interaction formed by Methyl Group**



1uze Enalaprilate – human testicular ACE1

### **Using the Tools**







#### **Best Practices**



- Molecular Design is interactive work, it needs to be practiced like an instrument.
- Besides optimizing attractive interactions, monitor repulsive ones.
- Target rigid portions first.
- Conformations and interactions cannot be separated.
- Carefully assess experimental structures:
  - Flectron densities
  - Invest into solving apo structures
  - Carefully analyze water networks
  - Assess key properties of pockets: rigid / induced two-state / induced with multiple conformations
  - Use overlays to solidify assessments (water / flexibility)
- Deconvolute larger ligands: Make compounds that lead to understanding which pockets, which moieties are giving what binding affinity
- Consciously push the boundaries of your models.

#### **Acknowledgments**



Bernd Kuhn
Jens-Uwe Peters
Wolfgang Haap
Michael Harder
François Diederich



We Innovate Healthcare